Thymalfasin

ApprovedSmall molecule

Thymalfasin is one of 262 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

261

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

Renal DialysisActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

COVID-19Active, not recruiting

Hepatitis CActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

Renal DialysisPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaApproved

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Thymalfasin

SSciClone Pharmaceuticals

Approved

2 2

Tricor

JJagotec

Preclinical

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

Statin

Bristol-Myers Squibb

Preclinical

1 5

Nadroparin

GSK

Preclinical

1 6

Selenium

SSWOG Cancer Research Network

Preclinical

1 7

Antithrombin-III

Octapharma

Preclinical

1 8

DAS181

AAnsun Biopharma, Inc.

Preclinical

4 9

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

1 10

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

COVID-19

NCT06821100

Q3 2027

Phase 2Active, not recruiting

Chemoradiotherapy

NCT06056804

Q4 2027

Phase 2Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06461910

Phase 2Recruiting

Colorectal Cancer

NCT06829355

Clinical

Trials by Indication[1]

Chemoradiotherapy2 trials

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Unknown status·—··NCT06024356·26 enrolled

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Active, not recruiting·—·Phase 2·NCT06056804·20 enrolled

Small Cell Lung Cancer2 trials

Abscopal Effect for Metastatic Small Cell Lung Cancer

Withdrawn·ZZhejiang Provincial People's Hospital·Phase 2·NCT02542137

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Unknown status·SSciClone Pharmaceuticals·Phase 1/2·NCT02906163·188 enrolled

Hepatocellular Carcinoma2 trials

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Unknown status·JJia Fan·Phase 4·NCT02281266·360 enrolled

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

Completed·SSciClone Pharmaceuticals·Phase 2·NCT00082082

Non-Small Cell Lung Cancer2 trials

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

Withdrawn·ZZhejiang Provincial People's Hospital·Phase 2·NCT02542930

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Unknown status·SSciClone Pharmaceuticals·Phase 2·NCT02906150·140 enrolled

COVID-192 trials

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

Terminated·RRhode Island Hospital·Phase 2·NCT04487444·56 enrolled

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT06821100·75 enrolled

8 more indications

Renal Dialysis1 trial

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

Completed·—·Phase 2·NCT04428008·262 enrolled

Metastatic Colorectal Cancer1 trial

Abscopal Effect for Metastatic Colorectal Cancer

Withdrawn·ZZhejiang Provincial People's Hospital·Phase 2·NCT02535988

Esophageal Cancer1 trial

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

Unknown status·HHangzhou Cancer Hospital·Phase 2·NCT02545751·29 enrolled

Effectiveness1 trial

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001036·12 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·ZZekuan Xu·Phase 2·NCT06461910·30 enrolled

Advanced Refractory Solid Tumors1 trial

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT05790447·60 enrolled

Hepatitis C1 trial

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Completed·SSciClone Pharmaceuticals·Phase 3·NCT00039962·500 enrolled

Colorectal Cancer1 trial

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Recruiting·—·Phase 2·NCT06829355·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Thymalfasin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thymalfasin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thymalfasin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SciClone Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSciClone Pharmaceuticals

Thymalfasin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

Chemoradiotherapy2 trials

Small Cell Lung Cancer2 trials

Hepatocellular Carcinoma2 trials

Non-Small Cell Lung Cancer2 trials

COVID-192 trials

Renal Dialysis1 trial

Metastatic Colorectal Cancer1 trial

Esophageal Cancer1 trial

Effectiveness1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Advanced Refractory Solid Tumors1 trial

Hepatitis C1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News